Corrections and Clarifications by 
Estrogenicity of Styrene
Oligomers and Assessment 
of Estrogen Receptor Binding
Assays
Polystyrene is frequently used in resins, and
the styrene dimers and trimers eluted from
polystyrene have been reported to have
estrogenic activity (1). We have performed
a number of in vitro and in vivo tests [i.e.,
estrogen receptor (ER) and androgen
receptor binding assays, thyroid hormone
receptor binding assays, human breast can-
cer cell line MCF-7 proliferation assays
(E-SCREEN), uterotrophic assays in imma-
ture and ovariectomized rats, Hershberger
assays, and prolactin release assays and
steroidogenesis] and found no effects of
styrene dimers or trimers on sex hormones
in any of these assays (2–7). These results
are supported by Fail et al. (8), who report-
ed that mixtures of styrene oligomers did
not show any estrogenic activity in the
immature rat uterotrophic assay and the
reporter gene assay. In addition, the Japan
Environment Agency referred to their stud-
ies (9) and removed the styrene dimers and
trimers from their list of endocrine disrup-
tors (9). However, Ohyama et al. (10)
reported that high concentrations of certain
styrene dimers and trimers showed estro-
genic effects in an ER binding assay and in
the E-SCREEN assay. Recently, several
assay systems have been used to assess
endocrine-disrupting effects, but a few of
these assay systems can cause false-positive
reactions when test compounds are at high
concentrations (11). 
To assess the accuracy of the ER binding
assay system and the results of Ohyama et al.
(10), and to ascertain the safety of styrene
dimers and trimers, we used a solubility test
and three ER binding assays (12) (Table 1).
The ER binding assay, which detects the
direct reactivity of ligand to a receptor, is the
most standardized and simple test system for
the detection of specific mechanisms of
estrogenic activity. 
Using the radiosotope method (Method
RI) as described previously (13,14), we
observed that styrene dimers and trimers
did not show statistically significant
inhibitory action against the binding of
[3H]-17β-estradiol (E2) to ER. 
We used Method A to detect the bind-
ing affinities of test samples to human ERα
(hERα). Using a fluorescence polarization
Screen-for-Competitor Kit ERα (Takara,
Kyoto, Japan) as described by Bolger et al.
(15), we measured the difference of polar-
ization between fluorescence-labeled E2
(ES1) bound to ER and ES1 only. Styrene
dimers and trimers did not show statistically
significant inhibitory action against the
binding of ESI to ER in this assay. 
We also used Method B, the method
used by Ohyama et al. (10), to detect the
binding affinities of test samples to the
human recombinant ERα coated on the
microplate by competition with fluores-
cence-labeled E2; this was performed using
the Estrogen Receptor (α) Competitor
Screening Kit (Wako PC, Osaka, Japan).
Styrene dimers and trimers showed weak
inhibitory effect on the binding of fluores-
cein E2 to hERα at 5 µmol/L, and their
binding abilities were < 30% in this assay. 
To evaluate the ER binding assays them-
selves, we included vitamin D3, naphthalene,
5α-dihydrotestosterone, and testosterone in
each of the three ER binding assays; none of
these compounds bound ER in vitro
(13,16,17). A cross-reaction between estro-
gen and androgens cannot occur in vivo
unless the androgens are metabolized. In
Method RI and Method A, these nonestro-
genic compounds did not show any ability to
bind to the ER. However, in Method B,
these compounds showed binding affinity
for the recombinant hERα coated on the
microplate at such high concentrations that
they did not dissolve, although the binding
affinity of E2 was similar in each assay.
These results suggest that Method B tends
to detect false-positive effects and that it is
less accurate at high concentrations because
of a decline of specificity to estrogen at high
concentrations at which compounds do not
dissolve. The manufacturer’s instructions for
the Estrogen Receptor (α) Competitor
Screening Kit used for Method B say to
“make sure there is no precipitation in the
solution.” Styrene dimers and trimers are so
hydrophobic that their solubility is very low
in the buffer solutions used in each assay.
On the basis of these results, styrene dimers
and trimers have no affinity for ER in
Methods RI and A. Nevertheless, styrene
dimers and trimers exhibited some affinity
for the recombinant hERα in the Method B
study, similar to that described by Ohyama
et al. (10), but at high concentrations such
that the compounds were not completely
dissolved. This result is not because of the
difference of sensitivity between rat ER and
human ER, as shown in Method A with
the use of hERα, but is caused by a
decrease in specificity to estrogen because
of the precipitation of test compounds. 
Ohyama et al. (10) reported that high
concentrations of styrene dimers and trimers
showed proliferative activity in the
E-SCREEN assay. Cell proliferation can be
induced by other growth factors, although
proliferation of MCF-7 cell is basically E2
dependent (18–20), and the response to E2
in MCF-7 cells varies because of the various
mutation of ER (21). Therefore, a false-posi-
tive response might only be shown in tests
using proliferation as a target. The luciferase
reporter gene assay, which indicates direct
gene expression reactivity through the recep-
tor, has been considered to be a more suit-
able assay for evaluating estrogenicity at the
cellular level because of specificity to E2
response (22,23). Styrene dimers and
trimers did not show any estrogenic effect in
the E-SCREEN assay and the reporter gene
assay in our previous study (6). In addition,
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Table 1. Solubility and binding affinity for ER of tested compounds. 
Solubilitya Binding affinity for ER (ED30) (µmol/L) 
Compounds (µmol/L) Method RI Method A Method B
Estrogenic compounds
17β-Estradiol > 10 0.0012*** 0.005*** 0.001***
Bisphenol A > 10  5.0*** 1.7*** 2.0**
Styrene dimers
2,4-Diphenyl-1-butene 1.3 NC NC > 10.0
cis-1,2-Diphenylcyclobutane 9.4 NC NC 10.0**
trans-1,2-Diphenylcyclobutane 4.0 NC NC > 10.0
Styrene trimers
2,4,6-Triphenyl-1-hexene < 0.16 NC NC > 10.0
1e-Phenyl-4e-(1-phenylethyl) tetralin < 0.16 NC NC > 10.0
1a-Phenyl-4e-(1-phenylethyl) tetralin < 0.16 NC NC > 10.0
1a-Phenyl-4a-(1-phenylethyl) tetralin 0.17 NC NC > 10.0
1e-Phenyl-4a-(1-phenylethyl) tetralin 0.16 NC NC 5.2**
1e-Phenyl-4a-(2-phenylethyl) tetralin < 0.16 NC NC > 10.0
1a-Phenyl-4a-(2-phenylethyl) tetralin < 0.16 NC NC > 10.0
Androgens
Testosterone < 10 NC NC 105.0***
5α-Dihydrotestosterone < 10 NC NC 45.0***
Nonestrogenic compounds
Vitamin D3 0.19 NC NC 100.0***
Naphthalene 100 NC NC 1010.0***
Abbreviations: ED30, concentration equivalent to 30% activity of 100 nmol/L E2; NC, no competition for binding of labeled
E2. Each value represents the mean of triplicate assays. .
aConcentration at which test compounds are saturated. **p < 0.01, ***p < 0.001 (vs. control, Dunnett test).at high concentrations at which test com-
pounds were precipitated, cells indicated an
abnormal response in the luciferase activity
of control plasmids and in morphology (data
not shown). To construct a stable assay sys-
tem, we used HeLa cells transfected with an
hERα expression plasmid derived from nor-
mal human liver ERα. In this assay system,
styrene dimers and trimers did not show any
increase in E2-dependent luciferase tran-
scription activity. These results agreed with
the result of the ER binding assay. We pre-
sume that styrene dimers and trimers had no
binding affinity to ER and they did not
affect E2-dependent transcription.
As a result, in our comparison of three
ER binding assays using estrogenic and
nonestrogenic compounds, it appeared that
Method RI and Method A were useful for
evaluating binding affinity for the ER, but
Method B, similar to the method of
Ohyama et al. (10), tended to indicate
false-positives in high concentrations in
which test chemicals were insoluble; this
reduced the specificity of ER to E2. Based
on our present results and previous reports
(2–7), we found no endocrine-disrupting
activities in styrene dimers and trimers elut-
ed from polystyrene-containing instant
noodle containers. 
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Estrogenicity of Styrene
Oligomers: Response to 
Ohno et al.
The main point of the letter by Ohno et al.
is that styrene oligomers have no estrogenic
activity, that our statement about “some
styrene oligomers having binding affinity
for hERα” was inaccurate, and that the
MCF-7 cell proliferation assay is useless in
detecting estrogenicity.
It seems that Ohno et al. have misunder-
stood our article. We are confident that the
results of the MCF-7 cell proliferative assay
and the binding assay of styrene oligomers to
hERα in our paper are accurate.
The inhibition of fluorescence-labeled
E2 binding to hERα by styrene oligomers
tested is shown in Figure 3 of our paper
(1). The inhibition by styrene trimers 1a-
phenyl-4e-(1´-phenylethyl)tetralin (ST-3)
and 1e-phenyl-4a-(1´-phenylethyl)tetralin
(ST-4) was detected at ≥ 5 × 10–7 M, and
the inhibition by styrene trimers 2,4,6-
triphenyl-1-hexene (ST-1), 1a-phenyl-
4a-(1´-phenylethyl)tetralin (ST-2), and
1e-phenyl-4e-(1´-phenylethyl)tetralin
(ST-5) was detected at ≥ 5 × 10–6 M,
both sufficiently soluble concentrations.
This means that ST-1, ST-2, ST-3, ST-4,
and ST-5 bound to hERα at “not high”
concentrations. The maximum inhibition
by styrene trimers (ST-1, ST-2, ST-3, ST-
4, and ST-5) was detected at 5 × 10–5 M;
this concentration is relatively low.
Although the maximum inhibition by
styrene dimers 1,3-diphenyl propane,
(SD-1), 2,4-diphenyl-1-butene (SD-2), cis-
1,2-diphenyl cyclobutane (SD-3), and
trans-1,2-diphenyl cyclobutane (SD-4) was
detected at 5 × 10–4 M, these styrene
trimers and dimers were almost soluble at 5
× 10–5 M and 5 × 10–4 M, respectively. It
is important that the inhibition hardly
increased at each 10-times-higher concen-
tration at which chemicals tested were par-
tially insoluble. This result indicates that
the soluble chemicals reacted with hER in
saturated solution, and insoluble com-
pounds did not influence the binding. In
Table 1 of their letter, Ohno et al. did not
clarify the solubility of the compounds. It
appears that the compounds were dissolved
in water because of the extremely low solubil-
ity. In our study we dissolved the compounds
in DMSO—the styrene dimers at 100,000
µmol/L and the styrene trimers at 10,0000
µmol/L, except for ST-2 (1,000 µmol/L).
Ohno et al. should have included the con-
centrations of the saturating chemicals in the
reaction solutions of each method in their
Table 1, because when various concentra-
tions of the chemical solvents (DMSO) are
added to the reaction solutions, the solubility
will become much higher. 
If our binding assay indicated false posi-
tives in the range of concentrations in
which test chemicals were insoluble, the
inhibition by 1e,3e,5a-triphenylcyclohexa-
ne (ST-6) and 1e,3e,5e-triphenylcyclohexa-
ne (ST-7) would also increase, but no bind-
ing activity was observed for ST-6 and ST-
7 at any concentration tested. This method
(Ohno et al.’s Method B) showed an
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some soluble styrene oligomers but no
effect by the same chemicals at insoluble
concentrations. Ohno et al.’s Method B
showed no ED30 values of the styrene
oligomers at > 10 µmol/L. Therefore,
Ohno et al.’s Method B also indicated no
effect by the styrene oligomers at insoluble
concentrations except testosterone, 5α-
dihydrotestosterone, vitamin D3, and
naphthalene. It seems that testosterone, 5α-
dihydrotestosterone, vitamin D3, and
naphthalene used by Ohno et al. had spe-
cial characteristics for the competitive bind-
ing assay kit (Wako, Osaka, Japan).
The MCF-7 cell proliferation assay is a
recognized method for estrogenic screening.
Ohno et al. overemphasize other growth
factors. All of the styrene oligomers we test-
ed did not have proliferative activity (1).
ST-6 and ST-7 had no proliferative activity
at all, but the proliferative potency of ST-3
and ST-4 was comparable with that of
bisphenol A. Moreover we confirmed that
OH-tamoxifen, an antagonist, inhibited
cell proliferation by ST-1, ST-3, ST-4, ST-
5, SD-3, and SD-4 (2). 
Recently, we reported that ST-1 and
ST-4 were estrogenic in the reporter gene
assay using MVLN cells established by sta-
ble transfection with the luciferase gene (3).
Moreover we found that some other styrene
oligomers were also estrogenic in this
reporter gene assay (2). 
We are confident that our paper (1)
does not include any inaccurate results.
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Corrections and Clarifications
In “3-Chloro-4-(dichloromethyl)-5-
hydroxy-2(5H)-furanone (MX) and
Mutagenic Activity in Massachusetts
Drinking Water” by Wright et al. [Environ
Health Perspect 110:157–164 (2002)],
there are two errors in “Materials and
Methods.” In lines 12–16 of the second
paragraph describing analytical protocol,
“700°C” should be “70°C” and “600
mg/L aqueous NaHCO3” should be “600
µg/L 2% aqueous NaHCO3.” The correct
sentences are as follows: 
The solution was heated to 70°C to accelerate
the reaction. The mixture was neutralized by
addition of 600 µg/L 2% aqueous NaHCO3
and extracted twice with 600 µL n-hexane.
EHP regrets the errors.
In “Certain Styrene Oligomers Have
Proliferative Activity on MCF-7 Human
Breast Tumor Cells and Binding Affinity
for Human Estrogen Receptor α” by
Ohyama et al. [Environ Health Perspect
109:699–703 (2001)], the grids in Figure
3 are incorrect. The corrected figure
appears at left. EHP regrets any confusion
caused by the incorrect grids.
Figure 3. The inhibition of fluorescence-labeled E2 binding to hERα by various concentrations of styrene
oligomers. Percent of inhibition was calculated as [1 – (optical density in the presence of competitor) ÷
(optical density in the absence of competitor)] × 100. Each point is the mean ± SD of two independent
assays performed in duplicate.
*Significantly different from hormone-free control (p < 0.01).